Bioanalysis · 2012 · 14 citations · 21 references
MedicinePharmacologyToxicologyBiochemical PharmacologyHepatotoxicologyMetabolomicsBiomarkers Of Liver InjuryHepatic FibrosisHepatic MetabolismHepatic PathophysiologyLiver DiseaseLiver Function TestsAspartate Aminotransferase ElevationBiomarkers Of Liver ToxicityClinical Chemistry BiomarkersHepatic Fibrosis BiomarkersLiver Fibrosis BiomarkersLiver Fibrosis ProgressionMetabolomic SignaturesSerum Aspartate Aminotransferase
BACKGROUND: A metabolomic study of biomarkers associated with dimethylnitrosamine (DMN)-induced hepatic fibrosis in Sprague-Dawley rats was performed using GC-MS. The clinical chemistry of the collected blood and the histopathology of excised liver samples were examined, and urine samples were prepared by solvent extraction. RESULTS: Through pattern analysis, the DMN-treated group was divided into two subgroups based on the aspartate aminotransferase (AST) levels compared with the control, a moderately higher group (DMN subgroup A) and a significantly higher group (DMN subgroup B). Uric acid, orotic acid, N-phenylacetylglycine and glutaric acid were biomarkers for DMN subgroup A, aminomalonic acid was a biomarker for DMN subgroup B, and arabitol level distinguished control versus DMN treatment regardless of AST level. CONCLUSION: This study suggests that the identification and profiling of AST level-related metabolites may be useful as a diagnostic tool and for the study of the mechanism of liver fibrosis induced by DMN.
21
Pharmaco-metabonomic phenotyping and personalized drug treatment
T. Andrew Clayton, John C. Lindon, Olivier Cloarec et al. · Nature · 2006 · 827 citations
Some Toxic Properties of Dimethylnitrosamine
Judith Barnes, Peter Magee · Occupational and Environmental Medicine · 1954 · 326 citations · Full text
Metabolic Activation of Drugs to Toxic Substances
Jerry R. Mitchell, David J. Jollows · Gastroenterology · 1975 · 283 citations
Medicine, Pharmacology, Toxicology +14